Ono Pharmaceutical Co Ltd (OPHLY)

4.46 -0.02 (-0.45%)
Close USD Disclaimer
4.46 -0.00 (-0.00%)

Ono Pharmaceutical Co Ltd Company Profile

Equity Type
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.
Contact Information
Osaka,541-8564 Japan
81 6 6263 5670
Top Executives
Yasuo Hishiyama 50 2016 Outside Audit & Supervisory Board Member
Akiko Tanabe 53 2020 Outside Audit & Supervisory Board Member
Hironobu Tanisaka 62 2021 Outside Audit Supervisory Board Member
Katsuyoshi Nishimura 69 2011 Chairman of Audit & Supervisory Board
Shusaku Nagae 73 2021 Independent Outside Director
Kiyoaki Idemitsu 59 2021 Managing Executive Officer, GM of Development Division & Director
Masao Nomura 74 2018 Independent Outside Director
Akiko Okuno 53 2020 Independent Outside Director
Gyo Sagara 66 2008 CEO & Chairman of the Board
Toshihiro Tsujinaka 60 2016 Ex. EO, Executive Dir. of Sus. Promotion Corp. Strategy & Planning and Representative Director
Toichi Takino 56 2020 President, COO & Representative Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles